but not with primary tumors. This implies either that the source of TGF-β is enriched in the bone-tumor microenvironment compared to primary tumors, or that the levels and activities of enzymes responsible for the release of TGF-β from the extracellular matrix are themselves elevated at the site of a decaying bone owing to the metastasis. Furthermore, the authors identified a loss of calstabin, and activation of SMAD3 and Nox4 (encoded by Nox4) in muscle biopsies from individuals affected with advanced breast and prostate cancer, which adds to the significance of their findings in the animal models. However, given the limited human sample sizes, these data will need to be repeated with properly powered cohorts in multiple tumor types associated with bone metastasis. These findings will also need to be correlated with circulating levels of TGF-β and proportional SMAD3 activity and Nox4 expression levels in skeletal muscles.
Perhaps most significantly, Waning et al. 5 identified several effectors within the TGF-β-Nox4-RyR1 signaling axis that could serve as therapeutic targets to prevent bone metastasisinduced muscle dysfunction. These include the use of chemical inhibitors (SD208 and bisphosphonate) and neutralizing antibodies (ID11) to directly target TGF-β signaling, all of which lowered SMAD3 phosphorylation Cachexia is a condition linked to chronic illnesses, and it is most easily diagnosed by a marked loss of body weight. Cachexia is distinct from anorexia or loss of appetite, conditions in which the loss of weight derives predominantly from the utilization of adipose stores, whereas skeletal muscle mass is preserved 1 . In cachexia, weight loss is derived from a reduction of muscle mass, and it contributes to an overall state of weakness and fatigue that, depending on the illness, can compromise treatment strategies and quality of life.
In cancer, cachexia is generally classified as a loss of more than 5% of a patient's pre-illness body weight, and it is estimated to occur in more than 80% of people with cancer 2, 3 . The gastrointestinal cancers, including esophageal and pancreatic cancer, are most commonly associated with cachexia, whereas malignancies such as breast and lung cancer are generally associated with cachexia only during late-stage disease 4 . A study in this issue of Nature Medicine 5 provides a new perspective on cachexia by highlighting the importance of muscle dysfunction in people with cancer, rather than the loss of lean tissue and fat mass. Furthermore, the study suggests that this reduction in muscle function occurs in patients with advanced disease, specifically with metastasis localized to bone.
Waning et al. 5 studied mouse models of tumor metastasis in which mice received injections of several tumor cell lines, including MDA-MB-231 and MCF-7 (breast), A549 and RWGT2 (lung), PC3 (prostate) and JJN3 (multiple myeloma). In these mice, the researchers were able to demonstrate that tumors that metastasize to bone and induce osteolysis cause the release of transforming growth factor-β (TGF-β) from the bone extracellular matrix into the general circulation ( Fig. 1) . In contrast to the physiological role of TGF-β that regulates cell growth and differentiation, the authors find that circulating, pathological levels of TGF-β activate a SMAD3 signaling pathway in both proximal and distal skeletal muscles that leads to the oxidation and nitrosylation of the ryanodine receptor 5 (RyR1). Under normal conditions, the protein calstabin stabilizes RyR1 (ref. 6 ). The loss of calstabin from the RyR1 complex, in conjunction with the post-translational modification of RyR1 in advanced cancers with bone metastasis, results in leaky Ca 2+ channels in the sarcoplasmic reticulum. This imbalance of Ca 2+ homeostasis presumably alters normal binding of Ca 2+ to troponin (a protein that is central to muscle contraction) in the sarcomere, leading to an impaired contractile apparatus and eventual muscle weakness. The authors further connected SMAD3 signaling to RyR1 oxidation in the muscle tissue of these mice by showing that TGF-β signaling through SMAD3 transcriptionally induces the NAPDH oxidase 4 (Nox4) gene, whose function in membranes results in the production of reactive oxygen species that oxidize multiple proteins, including RyR1. Thus, the authors showed that tumors that metastasize to bone and release TGF-β lead to lower muscle force production regardless of whether there is a reduction in muscle mass and body weight.
In the MDA-MB-231 breast tumor model, the authors also found that the degree of muscle weakness and leaky Ca 2+ channels both correlated with the extent of bone metastasis A TGF- pathway associated with cancer cachexia
Denis C Guttridge
Cancer cachexia leads to involuntary weight loss resulting from the atrophy of skeletal muscle and adipose tissues. Now, in metastatic mouse models of cancer, investigators reveal a cross talk pathway between bone and muscle that provides a new understanding of wasting in advanced cancers. Tumor cells npg disease (CED), a heritable human skeletal disease that is often associated with TGF-β mutations. Waning et al. 5 , showed that muscles from CED-model mice also have leaky RyR1 channels and contractile force deficits that are similar to those of mice with bone metastasis. However, they did not determine whether muscle weakness in CED-model mice is associated with reductions in muscle mass or changes in body weight that are attributable to the loss of lean and fat mass. The findings by Waning et al. 5 expand our understanding of cancer cachexia beyond the more commonly studied gastrointestinal cancers that are associated with severe weight loss. Activation of the SMAD3-Nox4 signaling axis, leading to muscle dysfunction, would not be predicted in people with gastrointestinal cancers because these cancers metastasize to soft tissue rather than bone 9 . However, it will be interesting to determine whether a role exists for TGF-β in these patients and in other mouse models without bone metastases. Furthermore, it should be tested whether the typical atrogene signature that accounts for the reduction in muscle mass and weight losscharacterized by elevated expression of genes encoding subunits of the ubiquitin proteasome and autophagy systems-is induced by TGF-β-triggered SMAD3 activation in mice and patients with bone metastasis. and prevented leaky RyR1 channels in muscles. In addition, to assess the role of RyR1 in cancer cachexia, investigators used the RyR1 channel stabilizer S107, which has been shown to improve muscle function in muscular dystrophy and aging 7, 8 . S107 functions by maintaining the interaction of calstabin with RyR1 independently of its effect on the posttranslational modifications of RyR1. Thus, the closed state of RyR1 is stabilized, preventing Ca 2+ leaks and deficits in muscular function. Mice with bone metastasis that were treated with S107 showed improved muscle function without changes to muscle mass or whole body weight. Finally, to ensure that post-translational modifications of RyR1 were responsible for the tumor-induced contractile dysfunction, mice with breast metastases were treated with the Nox4 inhibitor GKT137831, a drug that lowers oxidation and nitrosylation of proteins. GKT137831 prevented the metastasis-associated post-translational changes on muscle proteins, resulting in the stabilization of calstabin. These findings are particularly important, as no pharmacological therapy currently exists for cancer cachexia.
Another important connection made by the authors extends their findings beyond cancer cachexia. osteoclastic bone resorption and the release of TGF-β also occur in a nontumor mouse model of Camurati-Engelman Cachexia is characterized by ongoing loss of skeletal muscle mass that ultimately leads to progressive functional impairment 2 . The current findings from Waning et al. 5 potentially expand on this definition by suggesting that-at least in cancer-cachexia could include people who experience muscle dysfunction without loss of lean muscle or reductions in body weight. It will be intriguing in future clinical studies to assess whether deficits in muscle function correlate with advanced cancers that have progressed to bone metastasis, and more provocatively, whether people with these cancers would benefit from combinatorial therapies that include compounds that target the TGF-β-Nox4-RyR1 axis in order to enhance muscle contractility and performance.
The ability to culture normal human tissues or tumor biopsies as three-dimensional (3D) 'organoids' has recently emerged as a powerful tool for cancer research. Human cell lines are typically grown in two-dimensional monolayers, and although they are experimentally tractable and scalable, they often exhibit complex and/or undefined genetic backgrounds that do not always resemble the initial tumor. In animal models of cancer, there are multiple cell lineages, stroma and 3D organ structures; these models, however, are inherently limited in that they are not human, and experimental throughput is limited by their growth. organoid culture, by contrast, combines the advantages of human cell lines and animal models because these cultures model 3D tissue architecture and multilineage differentiation, and they even have stromal elements. Furthermore, robust experimental manipulation is possible. By using organoids, oncogenic mutations can be introduced into wild-type tissue, or conversely, organoids can be established from patient tumor samples. Numerous permutations of organoid-culture methods exist, including culture of wild-type epithelial cells taken from mature organs 1 or differentiated from hPSCs (ref.
2), culture of patient tumor samples 3, 4 , inclusion of stromal elements and the use of submerged extracellular matrices or air-liquid interfaces 1, 5 .
Pancreatic ductal adenocarcinoma (PDAC) is a lethal and poorly understood malignancy with limited treatment options. In this issue of Nature Medicine, Huang et al. 6 directly applied hPSC-derived pancreatic exocrine progenitor organoids to PDAC modeling using a multistep differentiation process. First, hPSCs were differentiated to pancreatic exocrine progenitors (as indicated by expression of the markers NKx6.1 -and PDx1) by established methods, including serial exposure to activin A for endodermal commitment, followed by glycogen synthase kinase (GSK3β) inhibition and the addition of basic fibroblast growth factor (bFGF), FGF10, noggin and exendin 4 to induce pancreatic differentiation 7 . Subsequently, the authors generated polarized 3D pancreatic exocrine progenitor organoids npg
